@article{9d585daa9d3948d9a80565c6c63404e9,
title = "Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054",
keywords = "adjuvants, autoimmunity, immunologic, immunotherapy, melanoma",
author = "Alexander Eggermont and Michal Kicinski and Stefan Suciu",
note = "Funding Information: Competing interests AE reports receiving personal fees from Biocad, BioInvent, BioNTech, BMS, CatalYm, Ellipses, GSK, IO Biotech, ISA Pharmaceuticals, Merck/ MSD, Nektar, Novartis, Pfizer, SAiRoPA, Sellas, SkylineDx, TigaTx, TTxDiscovery and owning equity in SkylineDx and SAiRoPA. MK reports receiving grants from Merck, BMS, and Pierre-Fabre. SS reports receiving grants from Merck, BMS, and Pierre-Fabre.",
year = "2022",
month = jan,
day = "18",
doi = "10.1136/jitc-2021-004272",
language = "English",
volume = "10",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BMJ Publishing Group",
number = "1",
}